Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17–48. https://doi.org/10.3322/caac.21763.

Article  PubMed  Google Scholar 

Marosi C, Köller M. Challenge of cancer in the elderly. ESMO Open. 2016;1:e000020. https://doi.org/10.1136/esmoopen-2015-000020.

Article  PubMed  PubMed Central  Google Scholar 

Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378:2078–92. https://doi.org/10.1056/NEJMoa1801005.

Article  CAS  PubMed  Google Scholar 

Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378:2288–301. https://doi.org/10.1056/NEJMoa1716948.

Article  CAS  PubMed  Google Scholar 

West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20:924–37. https://doi.org/10.1016/S1470-2045(19)30167-6.

Article  CAS  PubMed  Google Scholar 

Paz-Ares L, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:198–211. https://doi.org/10.1016/S1470-2045(20)30641-0.

Article  CAS  PubMed  Google Scholar 

Quoix E, Zalcman G, Oster JP, Westeel V, Pichon E, Lavolé A, et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet. 2011;378:1079–88. https://doi.org/10.1016/S0140-6736(11)60780-0.

Article  CAS  PubMed  Google Scholar 

Kogure Y, Iwasawa S, Saka H, Hamamoto Y, Kada A, Hashimoto H, et al. Efficacy and safety of carboplatin with nab-paclitaxel versus docetaxel in older patients with squamous non-small-cell lung cancer (Capital): a randomised, multicentre, open-label, phase 3 trial. Lancet Healthy Longev. 2021;2:e791–800. https://doi.org/10.1016/S2666-7568(21)00255-5.

Article  PubMed  Google Scholar 

Okamoto I, Nokihara H, Nomura S, Niho S, Sugawara S, Horinouchi H, et al. Comparison of carboplatin plus pemetrexed followed by maintenance pemetrexed with docetaxel monotherapy in elderly patients with advanced nonsquamous non-small cell lung cancer: a phase 3 randomized clinical trial. JAMA Oncol. 2020;6:e196828. https://doi.org/10.1001/jamaoncol.2019.6828.

Article  PubMed  PubMed Central  Google Scholar 

Yoh K, Hosomi Y, Kasahara K, Yamada K, Takahashi T, Yamamoto N, et al. A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy. Lung Cancer. 2016;99:186–93. https://doi.org/10.1016/j.lungcan.2016.07.019.

Article  PubMed  Google Scholar 

Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014;384:665–73. https://doi.org/10.1016/S0140-6736(14)60845-X.

Article  CAS  PubMed  Google Scholar 

Kubo T, Watanabe H, Ninomiya K, Kudo K, Minami D, Murakami E, et al. Immune checkpoint inhibitor efficacy and safety in older non-small cell lung cancer patients. Jpn J Clin Oncol. 2020;50:1447–53. https://doi.org/10.1093/jjco/hyaa152.

Article  PubMed  Google Scholar 

Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–8. https://doi.org/10.1038/bmt.2012.244.

Article  CAS  PubMed  Google Scholar 

Ramalingam SS, Dahlberg SE, Langer CJ, Gray R, Belani CP, Brahmer JR, et al. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol. 2008;26:60–5. https://doi.org/10.1200/JCO.2007.13.1144.

Article  CAS  PubMed  Google Scholar 

Wozniak AJ, Kosty MP, Jahanzeb M, Brahmer JR, Spigel DR, Leon L, et al. Clinical outcomes in elderly patients with advanced non-small cell lung cancer: results from ARIES, a bevacizumab observational cohort study. Clin Oncol (R Coll Radiol). 2015;27:187–96. https://doi.org/10.1016/j.clon.2014.12.002.

Article  CAS  PubMed  Google Scholar 

Laskin J, Crinò L, Felip E, Franke F, Gorbunova V, Groen H, et al. Safety and efficacy of first-line bevacizumab plus chemotherapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer: safety of avastin in lung trial (MO19390). J Thorac Oncol. 2012;7:203–11. https://doi.org/10.1097/JTO.0b013e3182370e02.

Article  CAS  PubMed  Google Scholar 

Yoshimura A, Yamada T, Okuma Y, Kitadai R, Takeda T, Kanematsu T, et al. Retrospective analysis of docetaxel in combination with ramucirumab for previously treated non-small cell lung cancer patients. Transl Lung Cancer Res. 2019;8:450–60. https://doi.org/10.21037/tlcr.2019.08.07.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ishida M, Morimoto K, Yamada T, Shiotsu S, Chihara Y, Yamada T, et al. Impact of docetaxel plus ramucirumab in a second-line setting after chemoimmunotherapy in patients with non-small-cell lung cancer: a retrospective study. Thorac Cancer. 2022;13:173–81. https://doi.org/10.1111/1759-7714.14236.

Article  CAS  PubMed  Google Scholar 

Katayama Y, Yamada T, Sawada R, Kawachi H, Morimoto K, Watanabe S, et al. Prospective observational study of ramucirumab plus docetaxel after combined chemoimmunotherapy in patients with non-small-cell lung cancer. Oncologist. 2024;2024:oyae001. https://doi.org/10.1093/oncolo/oyae001.

Article  Google Scholar 

Seto Y, Kaneko Y, Mouri T, Fujii H, Tanaka S, Shiotsu S, et al. Prognostic factors in older patients with wild-type epidermal growth factor receptor advanced non-small cell lung cancer: a multicenter retrospective study. Transl Lung Cancer Res. 2021;10:193–201. https://doi.org/10.21037/tlcr-20-894.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chrischilles EA, Link BK, Scott SD, Delgado DJ, Fridman M. Factors associated with early termination of CHOP therapy and the impact on survival among patients with chemosensitive intermediate-grade non-Hodgkin’s lymphoma. Cancer Control. 2003;10:396–403. https://doi.org/10.1177/107327480301000507.

Article  PubMed  Google Scholar 

Wright J, Doan T, McBride R, Jacobson J, Hershman D. Variability in chemotherapy delivery for elderly women with advanced stage ovarian cancer and its impact on survival. Br J Cancer. 2008;98:1197–203. https://doi.org/10.1038/sj.bjc.6604298.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Morris M, Platell C, Fritschi L, Iacopetta B. Failure to complete adjuvant chemotherapy is associated with adverse survival in stage III colon cancer patients. Br J Cancer. 2007;96:701–7. https://doi.org/10.1038/sj.bjc.6603627.

Article  CAS  PubMed  PubMed Central  Google Scholar 

O’Connor TL, Edge SB, Kossoff EB, Groman A, Wilding GE, Ademuyiwa FO, et al. Factors affecting the delivery of adjuvant/neoadjuvant chemotherapy in older women with breast cancer. J Geriatr Oncol. 2012;3:320–8. https://doi.org/10.1016/j.jgo.2012.06.006.

Article  Google Scholar 

Nebhan CA, Cortellini A, Ma W, Ganta T, Song H, Ye F, et al. Clinical outcomes and toxic effects of single-agent immune checkpoint inhibitors among patients aged 80 years or older with cancer: a multicenter international cohort study. JAMA Oncol. 2021;7:1856–61. https://doi.org/10.1001/jamaoncol.2021.4960.

Article  PubMed  Google Scholar 

Bellera CA, Rainfray M, Mathoulin-Pélissier S, Mertens C, Delva F, Fonck M, et al. Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. Ann Oncol. 2012;23:2166–72. https://doi.org/10.1093/annonc/mdr587.

Article  CAS  PubMed  Google Scholar 

Shiotsu S, Yoshimura A, Yamada T, Morimoto K, Tsuchiya M, Yoshioka H, et al. Pembrolizumab monotherapy for untreated PD-L1-Positive non-small cell lung cancer in the elderly or those with poor performance status: a prospective observational study. Front Oncol. 2022;12:904644. https://doi.org/10.3389/fonc.2022.904644.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Morimoto K, Yamada T, Takeda T, Shiotsu S, Date K, Harada T, et al. Prospective observational study evaluating the prognostic value of the G8 screening tool for extensive-stage small cell lung cancer patients who received programmed death-ligand 1 inhibitor plus platinum-etoposide chemotherapy. Drugs Aging. 2023;40:563–71. https://doi.org/10.1007/s40266-023-01034-4.

Article  CAS  PubMed  Google Scholar